PETER STEVEN KLEIN
Medical Practice in Penn Wynne, PA
License number
Pennsylvania MD055837L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Penn Wynne, PA 19096
Personal information
See more information about PETER STEVEN KLEIN at radaris.comName
Address
Phone
414 Park St, Mont Alto, PA 17237
543 Newtown Rd, Berwyn, PA 19312
305 Priscilla Ln, Aldan, PA 19018
85 Ferry Ln, Phoenixville, PA 19460
8302 Old York Rd APT B22, Elkins Park, PA 19027
Professional information
See more information about PETER STEVEN KLEIN at trustoria.com
Inhibitors Of Glycogen Synthase Kinase-3 And Methods For Identifying And Using The Same
Inhibitors Of Glycogen Synthase Kinase-3 And Methods For Identifying And Using The Same
US Patent:
6441053, Aug 27, 2002
Filed:
Jun 8, 1999
Appl. No.:
09/327660
Inventors:
Peter S. Klein - Wynnewood PA
Douglas Melton - Lexington MA
Douglas Melton - Lexington MA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
President and Fellows of Harvard University - Cambridge MA
President and Fellows of Harvard University - Cambridge MA
International Classification:
A61K 4700
US Classification:
514789, 424610, 514211, 514410, 514183, 435 15
Abstract:
A method of identifying inhibitors of glycogen synthase kinase-3 is provided. The method comprises providing a mixture comprising GSK-3, a phosphate source, and a GSK-3 substrate, incubating the mixture in the presence or absence of a test compound, and assessing the activity of GSK-3 in the mixture. A reduction of GSK-3 activity following incubation of the mixture in the presence of the test compound is an indication that the test compound is an inhibitor of GSK-3.
Regulation Of Gsk-3Alpha Activity For The Treatment Or Prevention Of Alzheimer's Disease
Regulation Of Gsk-3Alpha Activity For The Treatment Or Prevention Of Alzheimer's Disease
US Patent:
2010006, Mar 18, 2010
Filed:
Apr 30, 2008
Appl. No.:
12/150628
Inventors:
Christopher J. Phiel - Royersford PA, US
Christina A. Wilson - Lansdowne PA, US
Virginia M-Y. Lee - Philadelphia PA, US
Peter S. Klein - Wynnewood PA, US
Christina A. Wilson - Lansdowne PA, US
Virginia M-Y. Lee - Philadelphia PA, US
Peter S. Klein - Wynnewood PA, US
International Classification:
A61K 33/00, C12N 5/00, C12Q 1/48, A61P 25/28
US Classification:
424722, 435375, 435 15
Abstract:
Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (Aβ) peptides, which are now believed to be the principal cause of Alzheimer's disease, thereby providing methods useful for the prevention, inhibition or reversal of the disease. Also provided are methods of using agents that specifically target the α isoform of GSK-3, which is responsible for APP processing, making such selective GSK-3α-specific inhibitors especially useful in the treatment, prevention, and possible reversal of Alzheimer's disease. Further provided are kits and screening methods associated with the present methods.
Axin Domain-Like Polypeptide Inhibitors Of Glycogen Synthase Kinase 3 Beta Activity And Activators Of Wnt Signaling
Axin Domain-Like Polypeptide Inhibitors Of Glycogen Synthase Kinase 3 Beta Activity And Activators Of Wnt Signaling
US Patent:
2001005, Dec 13, 2001
Filed:
Mar 1, 2001
Appl. No.:
09/798831
Inventors:
Peter Klein - Wynnewood PA, US
Assignee:
Trustees of the University of Pennsylvania
International Classification:
A01K067/027, A61K038/55, C12N009/99
US Classification:
800/018000, 514/012000, 435/184000
Abstract:
The invention relates to polypeptides which inhibit the activity of glycogen synthase kinase-3 beta (GSK-3 beta) in vivo and which also activate wnt signaling. The polypeptides have an amino acid sequence which includes one or both of an axin/GSK-3 beta interaction domain (GID) and an axin/axin interaction domain (AID). These polypeptides are useful for treating a number of disorders (e.g. bipolar disorder, mania, depression, Alzheimer's disease, diabetes, and leukopenia) which are presently treated by administration of lithium. The invention also includes antibodies (including fragments of antibodies) which bind specifically with the polypeptides described in the disclosure, and to transgenic mice which comprise a transgene encoding such polypeptides.
Regulation Of Gsk-3Α Activity For The Treatment Or Prevention Of Alzheimer's Disease
Regulation Of Gsk-3Α Activity For The Treatment Or Prevention Of Alzheimer's Disease
US Patent:
7378111, May 27, 2008
Filed:
Feb 19, 2003
Appl. No.:
10/368769
Inventors:
Christopher J. Phiel - Royersford PA, US
Christina A. Wilson - Lansdowne PA, US
Virginia M-Y. Lee - Philadelphia PA, US
Peter S. Klein - Wynnewood PA, US
Christina A. Wilson - Lansdowne PA, US
Virginia M-Y. Lee - Philadelphia PA, US
Peter S. Klein - Wynnewood PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 33/14, A61K 33/00, A61P 25/28
US Classification:
424677, 424722, 514879
Abstract:
Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (Aβ) peptides, which are now believed to be the principal cause of Alzheimer's disease, thereby providing methods useful for the prevention, inhibition or reversal of the disease. Also provided are methods of using agents that specifically target the α isoform of GSK-3, which is responsible for APP processing, making such selective GSK-3α-specific inhibitors especially useful in the treatment, prevention, and possible reversal of Alzheimer's disease. Further provided are kits and screening methods associated with the present methods.
In Vivo And Ex Vivo Expansion Of Hematopoietic Stem Cells With A Targeted Combination Of Clinically Tested, Fda Approved Drugs
In Vivo And Ex Vivo Expansion Of Hematopoietic Stem Cells With A Targeted Combination Of Clinically Tested, Fda Approved Drugs
US Patent:
2011025, Oct 13, 2011
Filed:
Apr 11, 2011
Appl. No.:
13/084180
Inventors:
Peter S. Klein - Wynnewood PA, US
Jian Huang - Philadelphia PA, US
Jian Huang - Philadelphia PA, US
International Classification:
A61M 37/00, A61K 35/28, A61P 35/00, A61P 7/06, A61P 19/08, C12N 5/0775, A61P 35/02
US Classification:
604522, 435375, 435372, 435325, 424 937
Abstract:
The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions.